United Therapeutics Corp UTHR
Analyst Ratings
- Consensus
- Moderate Buy — 8 Buy · 2 Hold · 1 Sell (11 analysts)
- Avg. Price Target
- $618.64 (+14.2% upside)
Key Stats
- Today's Range
- $475.46 – $557.37
- 50-Day Range
- $468.97 – $557.37
- 52-Week Range
- $302.19 – $609.35
- Volume
- 3.34 million shs
- Average Volume
- 744K shs
- Market Cap
- $23.24 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 13.22%
- Days to Cover
- 14.04
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Related Stocks
Compare head-to-head: UTHR vs LLY·UTHR vs JNJ·UTHR vs ABBV·UTHR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.